Abstract
Pain in patients with impaired renal function may be a significant problem requiring treatment with opioids. However, pharmacokinetic and metabolic changes associated with an impaired renal function may raise some concerns about side effects and overdosing associated with opioid agents in this patients population. In order to give recommendations on this issue, we review the available evidences on the pharmacokinetics and side effects of most common opioids used to treat pain. The results of this review show that the half-life of the parent opioid compounds and of their metabolites is increased in the presence of renal dysfunction, for which careful monitoring of the patient, dose reduction and a longer time interval between doses are recommended. Among opioids, morphine and codeine used with great caution and possibly avoided in renal failure/dialysis patients; tramadol, hydromorphone and oxycodone can be used with caution and close patients monitoring, whereas transdermal buprenorphine, methadone and fentanyl/sufentanil appear to be safe to use in patients with renal failure.
Keywords: Analgesia, analgesics, buprenorphine, dialysis kidney, morphine, opioids, oxycodone, pain, renal failure
Current Drug Targets
Title: The Use of Major Analgesics in Patients with Renal Dysfunction
Volume: 11 Issue: 6
Author(s): Pasquale Niscola, Laura Scaramucci, Gisella Vischini, Marco Giovannini, Michele Ferrannini, Pasquale Massa, Paola Tatangelo, Massimo Galletti and Roberto Palumbo
Affiliation:
Keywords: Analgesia, analgesics, buprenorphine, dialysis kidney, morphine, opioids, oxycodone, pain, renal failure
Abstract: Pain in patients with impaired renal function may be a significant problem requiring treatment with opioids. However, pharmacokinetic and metabolic changes associated with an impaired renal function may raise some concerns about side effects and overdosing associated with opioid agents in this patients population. In order to give recommendations on this issue, we review the available evidences on the pharmacokinetics and side effects of most common opioids used to treat pain. The results of this review show that the half-life of the parent opioid compounds and of their metabolites is increased in the presence of renal dysfunction, for which careful monitoring of the patient, dose reduction and a longer time interval between doses are recommended. Among opioids, morphine and codeine used with great caution and possibly avoided in renal failure/dialysis patients; tramadol, hydromorphone and oxycodone can be used with caution and close patients monitoring, whereas transdermal buprenorphine, methadone and fentanyl/sufentanil appear to be safe to use in patients with renal failure.
Export Options
About this article
Cite this article as:
Niscola Pasquale, Scaramucci Laura, Vischini Gisella, Giovannini Marco, Ferrannini Michele, Massa Pasquale, Tatangelo Paola, Galletti Massimo and Palumbo Roberto, The Use of Major Analgesics in Patients with Renal Dysfunction, Current Drug Targets 2010; 11 (6) . https://dx.doi.org/10.2174/138945010791170879
DOI https://dx.doi.org/10.2174/138945010791170879 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Post Dural Puncture Headache and Hypertension
Current Hypertension Reviews Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Design and Synthesis of Dopaminergic Agonists
Current Medicinal Chemistry Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Management of Postoperative Nausea and Vomiting in Women Undergoing Major Gynecological Surgery: A Review and Update
Current Drug Therapy Development of Small Molecule Non-peptide Formyl Peptide Receptor (FPR) Ligands and Molecular Modeling of Their Recognition
Current Medicinal Chemistry Capsaicin Sensitive-Sensory Nerves and Blood Pressure Regulation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?
CNS & Neurological Disorders - Drug Targets TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Role of Hypocarbia in the Development of Cystic Periventricular Leukomalacia
Current Pediatric Reviews Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety
Current Medicinal Chemistry Hairy Roots, their Multiple Applications and Recent Patents
Recent Patents on Biotechnology Adverse Drug Reactions in Hospitals: A Narrative Review
Current Drug Safety Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Current Signal Transduction Therapy Platelet Aggregation and Exogenous Factors From Animal Sources
Current Drug Targets - Cardiovascular & Hematological Disorders New Mucoadhesive Polymeric Film for Ophthalmic Administration of Acetazolamide
Recent Patents on Drug Delivery & Formulation Drug Reinforcement in a Rat Model of Attention Deficit/Hyperactivity Disorder – The Spontaneously Hypertensive Rat (SHR)
Current Drug Abuse Reviews Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology